OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Schlick, Sandra (2010)
Languages: English
Types: Doctoral thesis
Subjects: QR, QH301

Classified by OpenAIRE into

mesheuropmc: hemic and lymphatic diseases, sense organs
Epstein-Barr virus (EBV) immortalises resting B-lymphocyctes and is associated with a\ud diverse range of cancers and establishes a persistent, latent infection in >90% of the\ud world-wide population. Epstein-Barr virus nuclear antigen (EBNA) 3C is one of only\ud six EBV latent proteins that are crucial for B-cell transformation. EBNA3C is known to\ud disrupt cell-cycle control and to progress phase transition at G1/S and G2/M under\ud conditions where cells should growth arrest, but the mechanism by which EBNA3C\ud does this has not been fully determined. The cell-cycle regulator response gene to\ud complement (RGC) 32 was found to be upregulated in EBNA3C-expressing cells in\ud microarray experiments carried out previously. RGC-32 is involved in cell-cycle\ud activation and also plays a role in G1/S and G2/M transition. I have shown that both\ud EBNA3C-expressing cell-lines with upregulated RGC-32 and cell-lines overexpressing\ud RGC-32 alone displayed disrupted G2/M checkpoint control indicating that EBNA3C\ud may overcome cell-cycle control by upregulation of RGC-32. I also confirmed that\ud RGC-32 increases the in vitro kinase activity of CDK1, the key mitotic kinase essential\ud for G2/M transition. Surprisingly, my data showed that EBNA3C only activated RGC-\ud 32 transcription in reporter assays at a very low-level, but stabilised the RGC-32\ud mRNA. Further studies investigating the differential expression of RGC-32 in EBVpositive\ud and negative cells demonstrated that RGC-32 is upregulated in LCLs and\ud tumour (Burkitt’s lymphoma) cell-lines expressing the full panel of latent genes, but\ud intriguingly highly expressed in Burkitt’s lymphoma cell-lines expressing only EBNA\ud 1. I found that this expression pattern correlated with expression of the RUNX1\ud transcription factor. Reporter assays revealed that RUNX1 was able to activate the\ud RGC-32 promoter. Together, this data indicates a new mechanism by which EBNA 3C\ud can disrupt the G2/M checkpoint and highlights a link between RUNX1 and RGC-32\ud expression in B-cells.

Share - Bookmark

Download from

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok